SCHOFIELD, Wis., April 18, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces its production vendors for the mass manufacturing and packaging of LipiGesic® M (www.lipigesic.com/about) its clinically tested, non-drowsy, migraine relief product.
“Through our current relationships with our third-party vendors, PuraMed has the established and proven infrastructure necessary to execute manufacturing, packaging, and distribution of LipiGesic M to an expanded number of retail outlets as orders are submitted,” said Russell Mitchell, CEO of PuraMed BioScience.
Product Manufacturing
PuraMed has contracted bulk manufacturing of LipiGesic products to Hillestad Pharmaceuticals, a Woodruff, Wisconsin-based, fully licensed prescription and OTC drug manufacturer. Hillestad also provides quality assurance testing. Hillestad Pharmaceuticals is fully compliant with all Good Manufacturing Practices (GMP) and other regulations set forth by the US Food and Drug Administration (FDA). www.hillestadlabs.com
Product Packaging
The bulk material is then packaged into individual, pre-measured unit dose sachets by the Unette Corporation in Randolph, New Jersey. Unette is fully licensed and compliant with all FDA regulations for the packaging of OTC products.
The external packaging including the box, box inserts, and 6-pack retail display trays has been awarded to Proteus Packaging located in Franklin, Wisconsin. Proteus has obtained the necessary certifications to ensure and maintain quality of the LipiGesic M product.
Online Distribution
PuraMed BioScience will utilize Great Lakes Fulfillment, of Lewiston, Maine for all of its e-commerce and retail distribution.
Expansion to Additional Retail Drug Chains
Currently, LipiGesic M is distributed in approximately 15,000 Walgreen’s and CVS/pharmacy stores across the United States. PuraMed plans to expand the retail placement of LipiGesic M, its clinically tested, natural migraine relief product into an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.
“With our manufacturing, packaging and fulfillment structure in place, PuraMed plans to ready its marketing and sales staff to begin the next phase of our product marketing campaign as we continue with our retail expansion plans,” said Mr. Mitchell.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com
Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contact:
Melissa Diaz,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com
SOURCE PuraMed BioScience, Inc.
